lisinopril, prednisone, pyridoxine, warfarin, and vitamin D. She reported using no additional herbals or supplements. Her only over-the-counter medication was as needed acetaminophen 650 mg, which she used about once a month. The patient smoked about 1 pack of cigarettes per day and reported no alcohol consumption. She reported no known family history of liver disease.
Liver enzymes were checked due to initiation of azathioprine therapy 2 days earlier (day 3 of therapy). Laboratory abnormalities were noted as follows: aspartate aminotransferase (AST) 43 U/L, alanine aminotransferase (ALT) 48 U/L, and alkaline phosphatase (ALP) 91 U/L (refer to Table 1 for reference ranges and baseline patient lab values). The patient's international normalized ratio (INR) was elevated to 4, and her warfarin dose was reduced. Her serum creatinine (SCr) was normal. Physical exam was normal with no abdominal pain, anorexia, fatigue, or nausea reported. Prior to starting azathioprine therapy, the patient's thiopurine methyltransferase (TPMT) genotype was found to be TPMT*1/TMPT*1, which is considered normal enzyme activity. With normal enzyme activity, the patient should be at less risk for hematologic toxicity, but the TPMT influence on the development of hepatotoxicity is not fully understood. 3 The patient's gastroenterologist was contacted; it was elected to continue her on the azathioprine titration and follow liver enzymes closely. On day 10 of therapy, her liver enzymes had increased further to AST 119 U/L, ALT 210 U/L, and ALP 460 U/L. Azathioprine was discontinued at that time. Her SCr remained normal. An INR collected on the same day was also elevated at 5.9. Consequently, warfarin was held for 2 days and the dose was reduced. The patient experienced no jaundice symptoms and only reported increased diarrhea, which was likely related to her Crohn's disease. Her viral serology was nonreactive for hepatitis B antigen. Hepatitis A and C were not tested. One week after discontinuing azathioprine, AST, ALT, and ALP had decreased significantly, and after 3 weeks had returned to baseline ( Table 1 ). The patient was then started on the tumor necrosis factor (TNF) inhibitor adalimumab to treat her Crohn's disease.
Discussion
The reported incidence of azathioprine-induced hepatotoxicity varies from less than 1% to 10%. 2, 3 It occurs almost exclusively in males. 1 There are multiple mechanisms by which azathioprine can cause liver damage. These include hypersensitivity reactions, idiosyncratic cholestatic reactions, and endothelial cell injury. 4 While this patient's liver injury was not an exact match for any one of these conditions, it most closely resembled acute cholestatic hepatitis, which is an ALT/ALP ratio less than 2 or ALP increase greater than twice the upper limit of normal. 5 The mechanism behind acute cholestatic hepatitis is unknown. It typically has a late onset, generally occurring 2 to 12 months after starting therapy. 1 Conversely, our patient is female and experienced hepatotoxicity within 3 days of starting the medication. Additionally, the bilirubin level is typically elevated in this condition, and our patient's level remained normal.
According to the Naranjo probability scale, the association between azathioprine and hepatotoxicity is classified as possible, 6 whereas the Council for International Organizations of Medical Sciences/Roussel Uclaf Causality Assessment Method (CIOMS/RUCAM) scale categorized this reaction as probable. 7 The CIOMS/RUCAM scale assesses the causal relationship between azathioprine and liver damage specifically. The rapid increase and decrease in liver enzymes after initiation and discontinuation, respectively, support the claim that azathioprine was the offending agent.
We conducted a MEDLINE search using the following Major MeSH terms: azathioprine adverse effects/contraindications/poisoning/toxicity and liver diseases/etiology or drug-induced liver injury or liver drug effects. The search was filtered to include only articles in the English language. A total of 98 articles were identified, of which 39 were about azathioprine-induced hepatotoxicity in humans. However, most of the articles focused on nodular regenerative hyperplasia hepatotoxicity, which occurs as a result of endothelial injury, has a latency period of at least 6 months, and produces minimal increase in ALT or ALP. Additionally, most case reports involved male patients. 1 Moses and colleagues reported a case of a 73-year-old Indian male patient treated with azathioprine for eye graft rejection who experienced fever and jaundice just 7 days after initiating therapy. Based on lab values, symptoms, and liver biopsy, the patient was determined to have acute cholestatic hepatitis. After discontinuing azathioprine, it took weeks for his symptoms to subside and months before lab values returned to normal. This case report has multiple differences from ours but highlights that acute cholestatic hepatitis can occur within days of initiating azathioprine. 8 A systemic review found the incidence of hepatotoxicity in patients with irritable bowel syndrome receiving azathioprine or mercaptopurine to be about 1% per year of treatment. 7 The onset of hepatotoxicity depended on the study and ranged from 1.5 to 5 months. 7 The first prospective epidemiological study by Bastida and colleagues found the incidence of hepatotoxicity to be 10% with a mean onset of 6 months. 9 There are multiple factors that can increase a patient's risk for hepatotoxicity. First, our patient was taking prednisone, which has been shown to increase the incidence of hepatotoxicity in patients treated with azathioprine therapy. In the study by Bastida and colleagues, 9 14 of 99 patients (14.1%) on azathioprine and concomitant corticosteroids experienced hepatotoxicity, which was defined as ALT or ALP levels more than twice the upper limit of normal in patients with previously normal levels. The median and mean onsets were 87 and 193 days, respectively. The concomitant prednisone therapy could have increased our patient's risk for hepatotoxicity, but it is not likely the sole cause as her liver enzymes remained stable and within the normal range while on prednisone prior to and after azathioprine therapy. Other viral causes such as hepatitis C, herpes simplex, Epstein-Barr, and cytomegalovirus were not tested. As stated previously, alcohol, over-the-counter medications, herbals/supplements, hepatitis B, and family history do not seem to play a causal role in this event.
Our patient's dose of 150 mg daily falls within the range of 2 to 2.5 mg/kg/day recommended for this condition by the American College of Gastroenterologists based on her weight of 70 kg. 10 It is unknown whether the weekly dose titration exacerbated her condition; however, her liver enzymes had increased by day 3 of therapy, which was before her titration started.
The increase in the patient's INR in spite of starting azathioprine should be noted. The interaction between warfarin and azathioprine has been well studied. 11 While the exact mechanism remains unknown, the addition of azathioprine to warfarin therapy appears to lower warfarin plasma concentrations, resulting in increased warfarin dose requirements of up to 2.5 times the baseline dose. Our patient's INR was stable at 2.5 ten days prior to starting azathioprine; it increased to 5.9 on day 10 of therapy despite a warfarin dose decrease. We believe the increased INR was a result of the patient's hepatotoxicity from azathioprine therapy. Of note, the INR dropped to 1.6 and then stabilized at 2.2 the following 1 and 2 weeks after stopping azathioprine, respectively.
This case report highlights that azathioprine hepatotoxicity can occur rapidly and in female patients when hepatotoxicity is less likely to occur. Our patient did not suffer any short-term adverse effects or known long-term adverse effects in the 6 months since this event occurred. Recommendations for monitoring liver function tests when initiating azathioprine vary. The British Association of Dermatologists recommends checking liver function tests weekly until a maintenance dose is achieved and then every 3 months. 8 MicroMedex and Lexi-Comp recommend monitoring every 2 weeks and 3 months, respectively. 2, 12 We believe that monitoring liver enzymes within the first week of azathioprine therapy should be considered, especially if the patient is taking corticosteroids or other highrisk medications that may be affected by hepatotoxicity such as warfarin. Further study to determine the best monitoring recommendations may be warranted.
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